USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
INNOVATIVE BIOTHERAPIES, INC.
Address:
650 Avis Drive, Suite 300
ANN ARBOR, MI
Phone:
(734) 213-8350
URL:
EIN:
175311291
DUNS:
143681240
Number of Employees:
20
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,751,980.00 5
SBIR Phase II $4,577,809.00 3

Award List:

Cell Therapy for Septic Shock

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Tissue engineering and cell therapy are a new and exciting approach to the treatment of acute and chronic diseases. The potential success of this therapeutic approach lies in the growing appreciation that most disease processes are not due to the lack of a single… More

Renal Tubules for a Bioartificial Kidney: Monolayer Differentiation of ES Cells

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$249,999.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Over 400,000 people are currently being treated for End-Stage Renal Disease (ESRD) in the United States, with the number of patients expected to grow dramatically over the next two decades. Organ transplantation is the optimal treatment for this disease, but at… More

Selective Cytopheresis Therapy in Systemic Inflammatory Response Syndrome

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$499,870.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): An extracorporeal device, named selective cytopheretic device (SCD), has been fabricated that sequesters activated leukocytes and inhibits their release of inflammatory proteins and cytokines. Leukocytes are major contr ibutors to the pathogenesis and progression… More

Enhanced Propagation of Adult Human Renal Epithelial Cells

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$137,388.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Available therapies for renal failure continue to be suboptimal with associated mortality rates of over 50% for acute renal failure (ARF) and a life expectancy for end stage renal disease (ESRD) of only 4-5 years. Curre nt renal replacement therapies are… More

Cell Therapy for Septic Shock

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$1,155,443.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Tissue engineering and cell therapy is a new and exciting approach to the treatment of acute and chronic diseases. The potential success of this therapeutic approach lies in the growing appreciation that most disease pr ocesses are not due to the lack of a single… More

Enhanced Propagation of Adult Human Renal Epithelial Cells Allowing for Commercia

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$1,990,126.00
Agency:
HHS
Principal Investigator:
Angela J. Westover
Abstract:
DESCRIPTION (provided by applicant): Renal cell therapy promises to improve the survival and overall health of patients suffering from acute renal failure (ARF), acute tubular necrosis (ATN), multiple organ failure (MOF), sepsis, cardiorenal syndrome (CRS) and end stage renal disease (ESRD). To… More

Selective Cytopheresis Therapy in Systemic Inflammatory Response Syndrome

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$1,432,240.00
Agency:
HHS
Principal Investigator:
Deborah A. Buffington – 734-213-8350
Abstract:
DESCRIPTION (provided by applicant): Leukocytes (LE) are major contributors to the pathogenesis and progression of many clinical inflammatory disorders, including the systemic inflammatory response syndrome, sepsis and acute respiratory distress syndrome.The need for new and innovative therapies to… More

Immunomodulatory Device for Treatment of Pediatric Acute Renal Failure Patients

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$364,723.00
Agency:
HHS
Principal Investigator:
Deborah A. Buffington – 734-997-7055
Abstract:
DESCRIPTION (provided by applicant): The Problem: The lack of devices specifically designed for pediatric applications has been recognized by directives in the Pediatric Medical Device Safety and Improvement Act of 2007, included in Public Law 110-85, andthe Institutes of Medicine, which has… More